Obesity continues to surge worldwide, and effective weight-loss strategies remain limited. The dual GIP/GLP-1 receptor agonist tirzepatide has demonstrated unprecedented weight reduction, spotlighting the therapeutic potential of incretin biology. Recent research shows that glucose-dependent insulinotropic polypeptide receptor (GIPR) activation exerts beneficial effects in the pancreas, central nervous system, and adipose tissue, contradicting earlier concerns that GIP promotes lipid storage.
Instead, GIPR agonism helps buffer lipids, prevents ectopic fat deposition, improves insulin sensitivity, and even mitigates GLP-1–related nausea while suppressing appetite. Despite paradoxical hypotheses favoring GIPR antagonism, accumulating evidence suggests that activating the receptor aligns with natural incretin physiology and enhances metabolic outcomes. This reframes GIP not as a…
